Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2...

by Rossi, Valentina, Berchialla, Paola, Giannarelli, Diana, Nisticò, Cecilia, Ferretti, Gianluigi, Gasparro, Simona, Russillo, Michelangelo, Catania, Giovanna, Vigna, Leonardo, Mancusi, Rossella Letizia, Bria, Emilio, Montemurro, Filippo, Cognetti, Francesco, Fabi, Alessandra
Published in Cancers (Basel) (2019)

Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study

by Fabi, Alessandra, De Laurentiis, Michelino, Caruso, Michele, Valle, Enrichetta, Moscetti, Luca, Santini, Daniele, Cannita, Katia, Carbognin, Luisa, Ciccarese, Mariangela, Rossello, Rosalba, Arpino, Grazia, Leonardi, Vita, Montemurro, Filippo, La Verde, Nicla, Generali, Daniele, Zambelli, Alberto, Scandurra, Giuseppa, Russillo, Michelangelo, Paris, Ida, D'Ottavio, Anna Maria, Filippelli, Gianfranco, Giampaglia, Marianna, Stani, Simonetta, Fabbri, Agnese, Alesini, Daniele, Cianniello, Daniela, Giannarelli, Diana, Cognetti, Francesco
Published in Oncotarget (2017)

“Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome

by Vici, Patrizia, Pizzuti, Laura, Sperduti, Isabella, Frassoldati, Antonio, Natoli, Clara, Gamucci, Teresa, Tomao, Silverio, Michelotti, Andrea, Moscetti, Luca, Gori, Stefania, Baldini, Editta, Giotta, Francesco, Cassano, Alessandra, Santini, Daniele, Giannarelli, Diana, Di Lauro, Luigi, Corsi, Domenico Cristiano, Marchetti, Paolo, Sini, Valentina, Sergi, Domenico, Barba, Maddalena, Maugeri-Saccà, Marcello, Russillo, Michelangelo, Mentuccia, Lucia, D'Onofrio, Loretta, Iezzi, Laura, Scinto, Angelo Fedele, Da Ros, Lucia, Bertolini, Ilaria, Basile, Maria Luisa, Rossi, Valentina, De Maria, Ruggero, Montemurro, Filippo
Published in Oncotarget (2016)